Pharmacotherapies for Alcoholism: Promising Agents and Clinical Issues

Alcoholism: Clinical and Experimental Research

Volumn 15, Issue 4, 1991, Pages 620-633

  Litten, Raye Z ^a   Allen, John P ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

Alcoholism; Pharmacotherapy

Indexed keywords

8 AZIDO 5,6 DIHYDRO 5 METHYL 6 OXO 4H IMIDAZO[1,5 A][1,4]BENZODIAZEPINE 3 CARBOXYLIC ACID ETHYL ESTER; ATENOLOL; BENZODIAZEPINE DERIVATIVE; BROMOCRIPTINE; CALCIUM CARBIMIDE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CHLORDIAZEPOXIDE; CITALOPRAM; CLONIDINE; DIAZEPAM; DISULFIRAM; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; LOFEXIDINE; LORAZEPAM; NITROUS OXIDE; OXAZEPAM; OXYGEN; PHENYTOIN; PLACEBO; PROPRANOLOL; ZIMELDINE;

ALCOHOLISM; CONFUSION; DRUG DEPENDENCE; DRUG THERAPY; DYSPHORIA; HUMAN; PRIORITY JOURNAL; REVIEW; SEIZURE; SHORT SURVEY; WITHDRAWAL SYNDROME;

ALCOHOL DETERRENTS; ALCOHOLISM; HUMAN; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0025943855     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/j.1530-0277.1991.tb00570.x     Document Type: Article

References (182)

1. Pharmacological treatment of alcohol intoxication, withdrawal, and dependence: A critical review
2. Acute ethanol poisoning and the ethanol withdrawal syndrome
3. Ethanol and the NMDA receptor
4. Diagnosis and treatment of alcohol withdrawal states
5. Alcohol withdrawal syndrome
6. Kindling as a model for alcohol withdrawal syndromes
7. Alcohol withdrawal and noradrenergic function
8. Alcohol detoxification and withdrawal seizures: Clinical support for a kindling hypothesis
9. An improved quantitative system for assessing the acute alcoholic psychoses and related states (TSA and SSA)
10. Decision for alcohol detoxification: A method to standardize patient evaluation
11. Development of optimal treatment tactics for alcohol withdrawal. I. Assess ment and effectiveness of supportive care
12. Use of an objective clinical scale in the assessment and management of alcohol withdrawal in a large general hospital
13. Detoxification of 1, 024 alcoholic patients with out psychoactive drugs
14. Nonpharmacologic intervention in acute alcohol withdrawal
15. Diazepam loading: Simplified treatment of alcohol with drawal
16. Special aspects of human alcohol withdrawal
17. Treatment Response and safety of ambulatory medical detoxication
18. Benzodiazepines in the treatment of alcoholism
19. Molecular interactions of ethanol with GABAergic system and potential of RO 15‐4513 as an ethanol antagonist
20. Catecholamine derived com pounds in urine and cerebrospinal fluid from alcoholics during and after long‐standing intoxication
21. Clinical studies on central noradrenergic activity in alcohol abusing patients
22. Minor tranquilizers, stress, and central catecholamine neurons
23. Benzodiazepines attenuate single unit activity in the locus coeruleus
24. Attenuating effect of diazepam on stress induced in noradrenaline turn‐ over in specific brain regions of rats: Antagonism by RO 15‐1788
25. The effect of alcohol, barbiturate, and diazepam on hypothalamic/pituitary adrenal function in chronic alcoholics
26. Hormonal changes in noncirrhotic male alcoholics during ethanol withdrawal
27. Clinical Neuroendocrinology and neuropharmacology of alcohol withdrawal
28. Circadian rhythms of cortisol during alcohol withdrawal
29. Benzodiazepine receptor antagonists reverse the effect of diazepam on plasma corticosterone in stressed rats
30. Relationship of the effects of the benzodiazepine derivative clorazepate on corticosterone secretion with its behavioural actions: Antagonism by RO 15‐1788
31. Neuropharmacological antagonism of the beta‐carboline‐induced “anxiety” response in rhesus monkeys
32. Alcohol intoxication and withdrawal
33. The pharmacotherapy of alcoholism
34. Emerging treatment options in the alcohol with drawal syndrome
35. Relative amnesic actions of diazepam, flunitrazepam, and lorazepam in man
36. Pharmacologic treatment of chronic alcoholism
37. The amnesic action of benzodiazepines in man
38. Benzodiazepine dependency in alcoholics
39. Randomized clinical trial of atenolol in patients with alcohol withdrawal
40. The efficacy of atenolol in the outpatient management of the alcohol withdrawal syndrome
41. Propranolol‐ associated confused states during alcohol withdrawal
42. Clonidine and alcohol withdrawal
43. Clonidine in alcohol withdrawal
44. Efficacy of clonidine in treatment of alcohol withdrawal state
45. Alcohol withdrawal syndromes: Clinical management with lofexidine
46. Clonidine vs chlordiazepoxide in the management of acute alcohol withdrawal syndrome
47. Alcohol withdrawal syndrome: Clinical and hormonal responses to alpha 2‐adrenergic agonist treatment
48. Alcohol withdrawal: Effects of clonidine treatment on sympathetic activity, the renin‐aldosterone system, and clinical symptoms
49. Is clonidine useful in the treatment of alcohol withdrawal
50. Control of acute alcoholic withdrawal symptoms: A comparative study of haloperidol and chlordiazepoxide
51. Clinical assessment and pharmacotherapy of the alcohol withdrawal syndrome
52. Alcohol and Seizures
53. The treatment of alcoholic withdrawal states with oxygen and nitrous oxide
54. Analgesic nitrous oxide for alcohol withdrawal: A critical appraisal after 10 years' use
55. A comparison of the effects of morphine sulphate and nitrous oxide analgesia on chronic pain states in man
56. Consumption of ethanol solution is potentiated by morphine and attenuated by naloxone persistently across repeated daily administrations
57. Alcoholism: Scientific basis of a neuropsychogenetic disease
58. Naltrexone and the treatment of alcohol‐dependence: Initial observations
59. Alcohol intoxication and physical dependence: A molecular mystery tour
60. Ethanol and neuronal calcium channels
61. Pharmacological basis for the use of nimodipine in central nervous system disorders
62. Calcium channel antagonists decrease the ethanol withdrawal syndrome
63. Nifedipine delays the acquisition of tolerance to ethanol
64. Effects of dihydropyridine calcium channel antagonists in tethanol withdrawal, doses required stereospecificity and actions of Bay K 8644
65. Increased dihydropyridine‐sensitive calcium channels in rat brain may underlie ethanol physical dependence
66. Are changes in neuronal calcium channels involved in ethanol tolerance
67. Cortical dihydropyridine binding sites are unaltered in human alcoholic brain
68. Calcium channel antagonist receptors in cerebral cortex from alcoholic patients
69. Calcium‐channel‐ blocking agent in the treatment of acute alcohol withdrawal‐caroverine versus meprobamate in a randomized double‐blind study
70. Alcohol withdrawal and carbamazepine
71. Double‐blind controlled trial comparing carbamazepine to oxazepam treatment of alcohol withdrawal
72. Alcohol and central serotonin metabolism in man
73. Serotonin and ethanol preference
74. Zimelidine‐induced variations in alcohol intake by nondepressed heavy drinkers
75. The serotonin uptake inhibitor citalopram attenuates ethanol intake
76. Reduction in alcohol intake in humans as a function of treatment with zimelidine: Implications for treatment
77. Effect of fluoxetine on alcohol consumption in male alcoholics
78. Serotonin uptake blockers and the treatment of alcoholism
79. Differential effects of viqualine on alcohol intake and other consummatory behaviors
80. Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers
81. Serotonin uptake inhibitors attenuate ethanol intake in problem drinkers
82. Neuropsychological recovery in alcoholics: Endogenous and exogenous processes
83. Alcohol and the brain: Neuropsychological correlates
84. Neuropsychologically impaired alcoholics: Assessment, treatment considerations, and rehabilitation
85. Serotonin uptake inhibitors: Pharmacotherapy for relapse prevention in alcoholics
86. Zimelidine effects on memory impairments produced by ethanol
87. Interactions of serotonin with ethanol: Clinical and animal studies
88. Determinants of Relapse: Implications for the maintenance of behavior change
89. The frequency and persistence of depressive symptoms in the alcohol abuser
90. Serotonin reuptake blockers in vitro and in vivo
91. 5‐Hydroxytryptophan‐induced conditioned taste aversion to ethanol in the rat
92. Conditioned taste aversion to ethanol induced by zimelidine
93. Bromocriptine in the prevention of alcohol abuse
94. Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics
95. Oral ethanol reinforcement in the rat: Effect of the partial inverse benzodiazepine agonist RO 15‐4513
96. Naltrexone blocks the post‐ shock increase of ethanol consumption
97. Antagonism by naltrexone of voluntary alcohol selection in the chronically drinking macaque monkey
98. The clinical use of disulfiram (Antabuse): A review
99. Disulfiram neuropathy: A review (1971‐1988) and report a case
100. Disulfiram treatment of alcoholism
101. An evaluation of the use of tetraethyl‐thiuram disulfide in the treatment of 560 cases of alcohol addiction
102. Control orientation and disulfiram
103. Brief report: Disulfiram acceptors and refusers: Do they differ
104. A comparison of disulfiram acceptors and refusers on selected demographic and clinical characteristics
105. Disulfiram for the treatment of alcoholism
106. Disulfiram treatment of alcoholism: A Veterans Administration Cooperative Study
107. Spouse contracting to increase antabuse compliance in alcoholic veterans
108. Antabuse contracts for married alcoholics and their spouses: A method to maintain Antabuse ingestion and decrease conflict about drinking
109. Probation linked supervised disulfiram in the treatment of habitual drunken offenders: Results of a pilot study
110. Mandatory supervised Antabuse therapy in an outpatient alcoholism program: A pilot study
111. Alcoholism treat ment by disulfiram and community reinforcement therapy
112. A double‐blind placebo controlled study of male alcoholics given a subcutaneous disulfiram implantation
113. Comparative aspects of disulfiram and its metabolites in the disulfiram‐ethanol reaction in the rat
114. m aldehyde dehydrogenase inhibitor
115. The co‐occurrence of alcoholism with other psychiatric disorders in the general population and its impact on treatment
116. Alcoholism, anxiety, and depression
117. Prospects for a rational pharmacotherapy of alcoholism
118. Outpatient treat ment of patients with substance abuse and coexisting psychiatric disorders
119. Psycho‐ pathology as a predictor of treatment outcome in alcoholics
120. Anxiety and depression in sub stance abuse: Clinical implications
121. Imipramine disposition in alcoholics
122. Posttreatment depression in an alcohol and drug abuse population
123. Changes in depression among abstinent alcoholics
124. Dropping out of Treatment: A critical review
125. Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers
126. Efficacy of fluoxetine in outpatients with major depression
127. Recent studies on selective serotonergic antidepressants: Trazodone, fluoxetine, and fluvoxamine
128. An evaluation of the effects of lithium in the treatment of chronic alcoholism. 11. Assessment of the two‐period crossover design
129. Lithium compliance in alcoholic males: A six‐month follow‐up study
130. A double‐blind, placebo‐controlled trial of lithium carbonate therapy for alcoholism
131. Does lithium carbonate therapy for alcoholism deter relapse drinking
132. Lithium treatment of depressed and nondepressed alcoholics
133. Pharmacological and clinical effects of buspirone
134. Buspirone in the treatment of alcoholic patients
135. Anxiety disorders coexisting with substance dependence: Treatment with buspirone
136. Buspirone attenuates volitional alcohol intake in the chronically drinking monkey
137. Buspirone alters alcohol drinking induced in rats by tetrahydropapaveroline injected into brain monoaminergic pathways
138. An open trial of buspirone in alcoholics
139. Cocaine and alcoholism: Distinct or part of a spectrum
140. Alcohol and opioids: Possible interactions of clinical importance
141. Alcoholism among methadone patients: A specific treatment method
142. A behavioral treatment of alcoholic methadone patients
143. The treatment of alcoholic methadone patients: A review
144. Methadone maintenance and patients in alcoholism treatment
145. Multiple drug use in alcoholics: Practical and theoretical implications
146. The relevance to clinical care of recent research in neurobiology
147. Adaptive responses to ethanol in the central nervous system
148. Arousal of ethanol‐intoxicated comatose patients with naloxone
149. Lithium antagonizes ethanol intoxication in alcoholics
150. Thyrotropin‐releasing antagonism of ethanol inebriation
151. Is ethanol antagonist RO15‐4513 selective for ethanol
152. Is RO15‐4513 a specific alcohol antagonist
153. Attenuation of ethanol intoxication by alpha‐2 adrenoceptor antagonists
154. Structural requirements for neurohypophyseal peptide maintenance of ethanol tolerance
155. 1 characteristics mediate the maintenance of ethanol tolerance by vasopressin
156. Forskolin promotes the development of ethanol tolerance in 6‐hydroxydopamine‐treated mice
157. Cyclooxygenase inhibitors antagonize the depressant effects of ethanol: Potency correlations with ethanol‐induced loss of the righting reflex
158. N‐methyl‐D‐aspartate receptors and ethanol: Inhibition of calcium flux and cyclic GMP production
159. Ethanol inhibits NMDA‐ activated ion current in hippocampal neurons
160. Gene expression in rat brain
161. Ethanol and guanine nucleotide binding proteins: A selective interaction
162. Hippocampal and cerebellar beta‐adrenergic receptors and adenylate cyclase are differentially altered by chronic ethanol ingestion
163. Human leukocyte beta‐adrenergic stimulated cyclic AMP in ethanol intoxication and withdrawal
164. Acute and chronic effects of ethanol on receptor‐mediated phosphatidylinositol 4, 5‐bisphosphate breakdown in mouse brain
165. Cerebrospinal fluid corticotropin‐releasing hormone in depression: Relation ship to noradrenergic function
166. Cholecystokinin and satiation with alcohol
167. Postponement of satiety by blockade of brain cholecystokinin (CCK‐B) receptors
168. Angiotensin converting enzyme inhibitors reduce alcohol consumption: Some possible mechanisms and important conditions for its therapeutic use
169. Rat self administration of ethanol: Enhancement by darkness and exogenous melatonin
170. Pineal gland and melatonin influence on chronic alcohol consumption by hamsters
171. Carbohydrates and depression
172. Ethanol enhancement of isoproterenol‐stimulated melatonin and cyclic AMP release from cultured pineal glands
173. HLA antigens as immunogenetic markers of alcoholism and alcohol liver disease
174. Association and linkage between alcoholism and eleven serological markers
175. Suggestive evidence of genetic linkage between alcoholism and the MNS blood group
176. Possible linkage between alcoholism and esterase‐D
177. 2 receptor gene in alcoholism
178. Heroin addiction
179. Increased effectiveness of substance abuse treatment: A prospective study of patient‐treatment “matching
180. Psychiatric severity as predictor of benefits from psychotherapy. The Penn‐VA study
181. Matching alcoholics to coping skills as interactional therapies: Posttreatment results